Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia
Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemother...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Pharmaceutical Association (1996) 1999-09, Vol.39 (5), p.706 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 706 |
| container_title | Journal of the American Pharmaceutical Association (1996) |
| container_volume | 39 |
| creator | Adams, V R Brenner, T |
| description | Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemotherapy to maintain the high-dose regimen that may provide a survival advantage for the patient with cancer. Additional product information is available at www.ahp.com/products/neumega.htm. |
| doi_str_mv | 10.1016/S1086-5802(15)30363-6 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_10533354</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10533354</sourcerecordid><originalsourceid>FETCH-LOGICAL-p122t-caf07d42f7be688314e66793d1d79c888c10b85f55431220405bc43b706ad61d3</originalsourceid><addsrcrecordid>eNo9j81KAzEYRbNQbK0-gpJlC45-mS_JpEsptQrFLtR1yW87OtMJmVTp21vwZ3G5cOAeuIRcMbhlwOTdCwMlC6GgHDMxQUCJhTwhw388IOd9_w6AgpXqjAwYCEQUfEgWq5h88-k_6h0dP_t96zd6ckNDnfpMY6Ozb3ymm9R95S0N2uYu0XBM3qauNZ095C76Xa0vyGnQTe8vf3tE3h7mr7PHYrlaPM3ul0VkZZkLqwNUjpehMl4qhYx7KaspOuaqqVVKWQZGiSAEx-MAOAhjOZoKpHaSORyR6x9v3JvWu3VMdavTYf33CL8BmihMGw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Adams, V R ; Brenner, T</creator><creatorcontrib>Adams, V R ; Brenner, T</creatorcontrib><description>Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemotherapy to maintain the high-dose regimen that may provide a survival advantage for the patient with cancer. Additional product information is available at www.ahp.com/products/neumega.htm.</description><identifier>ISSN: 1086-5802</identifier><identifier>DOI: 10.1016/S1086-5802(15)30363-6</identifier><identifier>PMID: 10533354</identifier><language>eng</language><publisher>United States</publisher><subject>Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Blood Platelets - drug effects ; Humans ; Interleukin-11 - therapeutic use ; Recombinant Proteins - therapeutic use ; Thrombocytopenia - chemically induced ; Thrombocytopenia - drug therapy</subject><ispartof>Journal of the American Pharmaceutical Association (1996), 1999-09, Vol.39 (5), p.706</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10533354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adams, V R</creatorcontrib><creatorcontrib>Brenner, T</creatorcontrib><title>Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia</title><title>Journal of the American Pharmaceutical Association (1996)</title><addtitle>J Am Pharm Assoc (Wash)</addtitle><description>Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemotherapy to maintain the high-dose regimen that may provide a survival advantage for the patient with cancer. Additional product information is available at www.ahp.com/products/neumega.htm.</description><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Blood Platelets - drug effects</subject><subject>Humans</subject><subject>Interleukin-11 - therapeutic use</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Thrombocytopenia - chemically induced</subject><subject>Thrombocytopenia - drug therapy</subject><issn>1086-5802</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9j81KAzEYRbNQbK0-gpJlC45-mS_JpEsptQrFLtR1yW87OtMJmVTp21vwZ3G5cOAeuIRcMbhlwOTdCwMlC6GgHDMxQUCJhTwhw388IOd9_w6AgpXqjAwYCEQUfEgWq5h88-k_6h0dP_t96zd6ckNDnfpMY6Ozb3ymm9R95S0N2uYu0XBM3qauNZ095C76Xa0vyGnQTe8vf3tE3h7mr7PHYrlaPM3ul0VkZZkLqwNUjpehMl4qhYx7KaspOuaqqVVKWQZGiSAEx-MAOAhjOZoKpHaSORyR6x9v3JvWu3VMdavTYf33CL8BmihMGw</recordid><startdate>199909</startdate><enddate>199909</enddate><creator>Adams, V R</creator><creator>Brenner, T</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>199909</creationdate><title>Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia</title><author>Adams, V R ; Brenner, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p122t-caf07d42f7be688314e66793d1d79c888c10b85f55431220405bc43b706ad61d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Blood Platelets - drug effects</topic><topic>Humans</topic><topic>Interleukin-11 - therapeutic use</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Thrombocytopenia - chemically induced</topic><topic>Thrombocytopenia - drug therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>Adams, V R</creatorcontrib><creatorcontrib>Brenner, T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of the American Pharmaceutical Association (1996)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adams, V R</au><au>Brenner, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia</atitle><jtitle>Journal of the American Pharmaceutical Association (1996)</jtitle><addtitle>J Am Pharm Assoc (Wash)</addtitle><date>1999-09</date><risdate>1999</risdate><volume>39</volume><issue>5</issue><spage>706</spage><pages>706-</pages><issn>1086-5802</issn><abstract>Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemotherapy to maintain the high-dose regimen that may provide a survival advantage for the patient with cancer. Additional product information is available at www.ahp.com/products/neumega.htm.</abstract><cop>United States</cop><pmid>10533354</pmid><doi>10.1016/S1086-5802(15)30363-6</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1086-5802 |
| ispartof | Journal of the American Pharmaceutical Association (1996), 1999-09, Vol.39 (5), p.706 |
| issn | 1086-5802 |
| language | eng |
| recordid | cdi_pubmed_primary_10533354 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Blood Platelets - drug effects Humans Interleukin-11 - therapeutic use Recombinant Proteins - therapeutic use Thrombocytopenia - chemically induced Thrombocytopenia - drug therapy |
| title | Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T13%3A05%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oprelvekin%20(Neumega),%20first%20platelet%20growth%20factor%20for%20thrombocytopenia&rft.jtitle=Journal%20of%20the%20American%20Pharmaceutical%20Association%20(1996)&rft.au=Adams,%20V%20R&rft.date=1999-09&rft.volume=39&rft.issue=5&rft.spage=706&rft.pages=706-&rft.issn=1086-5802&rft_id=info:doi/10.1016/S1086-5802(15)30363-6&rft_dat=%3Cpubmed%3E10533354%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/10533354&rfr_iscdi=true |